Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluated changes in healthcare resource utilization (HCRU) and costs of care within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially insured and Medicare Advantage (MA) lives in the U.S among adult patients with heart failure with reduced ejection fraction (HFrEF) (cohort 1) and adult patients with chronic heart failure (CHF) (cohort 2).
This was a non-interventional, retrospective cohort study using secondary data sources from the Optum Clinformatics® Data Mart (CDM) and 100% files of the CMS Medicare RIFs.
Two study cohorts were constructed to include adult Heart Failure with reduced ejection fraction (HFrEF) patients who newly initiated sacubitril/valsartan (Cohort 1) and adult Chronic Heart Failure (CHF) patients who newly initiated sacubitril/valsartan (Cohort 2).
The date of first prescription fill for sacubitril/valsartan during the cohort identification period was defined as index date. A 12-month washout period was employed to ascertain the "new user" status. The Healthcare Resource Utilization (HCRU) and costs of care outcomes will be measured within both the 12 months post-index period and the 12 months pre-index period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 - Adult HFrEF patients | adult HFrEF patients who newly initiated sacubitril/valsartan |
| |
| Cohort 2 - Adult CHF patients | adult CHF patients who newly initiated sacubitril/valsartan |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| sacubitril/valsartan | Drug | Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2). |
| Measure | Description | Time Frame |
|---|---|---|
| Mean number of Heart Failure - specific hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Number of Heart Failure (HF)-specific hospitalizations was defined as the number of acute inpatient hospitalizations with a primary discharge diagnosis of HF. An acute inpatient hospitalization was defined as a medical claim for an inpatient hospitalization. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Measure | Description | Time Frame |
|---|---|---|
| Mean number of HF - related hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Number of HF-related hospitalizations was defined as the number of acute inpatient hospitalizations with a discharge diagnosis of HF in any position. | Baseline, 12 months post initiation of sacubitril/valsartan |
Not provided
Inclusion Criteria:
Cohort 1 - Adult HFrEF patients
Cohort 2 - Adult CHF patients
Exclusion Criteria:
- Patients who died during the post-index period will be excluded.
Not provided
Not provided
adult patients with heart failure with reduced ejection fraction (HFrEF) and adult patients with chronic heart failure (CHF)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | East Hanover | New Jersey | 07936-1080 | United States |
Not provided
| Label | URL |
|---|---|
| Results for CLCZ696BUS33 from the Novartis Clinical Trials Website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C549068 | sacubitril and valsartan sodium hydrate drug combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Mean number of all-cause hospitalizations of adult HFrEF patients treated with sacubitril/valsartan |
Number of all-cause hospitalizations was as the number of acute inpatient hospitalizations for any reason. |
| Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean number of Urgent Heart Failure (UHF) visits of adult HFrEF patients treated with sacubitril/valsartan | An UHF visit was defined as any of the following: i) a patient with a place of service (POS) code 20, which corresponds to urgent care facility ii) a patient with an ER visit that was outpatient (POS code = 22, 23), identified from revenue codes: 0450, 0451, 0452, 0456 or 0459 iii) a patient with an urgent care clinic visit that was outpatient (POS code = 22, 23), identified from revenue codes: 0516 or 0526 iv) a patient with a hospital observational stay (POS code = 22, 23), identified from revenue code 0762 | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean number of Worsening Heart Failure (WHF) episodes of adult HFrEF patients treated with sacubitril/valsartan | Number of WHF episodes was defined as a composite outcome of HF-specific hospitalizations and UHF visits. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean costs of HF-specific hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Costs of HF-specific hospitalizations was defined as the sum of payer paid amounts for acute inpatient hospitalizations with a primary discharge diagnosis of HF. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean costs of HF-related hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Costs of HF-related hospitalizations were defined as the sum of payer paid amounts for acute inpatient hospitalizations with a discharge diagnosis of HF in any position. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean costs of all-cause hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Costs of all-cause hospitalizations were defined as the sum of payer paid amounts for acute inpatient hospitalizations for any reason. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean costs of UHF visits of adult HFrEF patients treated with sacubitril/valsartan | Costs of UHF visits were defined as the sum of payer paid amounts for UHF visits. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean costs of WHF episodes of adult HFrEF patients treated with sacubitril/valsartan | Costs of WHF episodes were defined as the sum of payer paid amounts for HF-specific hospitalizations and UHF visits. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean HF-specific costs of adult HFrEF patients treated with sacubitril/valsartan | HF-related costs were defined as the sum of payer paid amounts for medical claims with a diagnosis of HF in any position. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean all-cause medical costs of adult HFrEF patients treated with sacubitril/valsartan | All-cause medical costs were defined as the sum of payer paid amounts for all medical claims. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean all-cause pharmacy costs of adult HFrEF patients treated with sacubitril/valsartan | All-cause pharmacy costs were defined as the sum of payer paid amounts for all pharmacy claims. | Baseline, 12 months post initiation of sacubitril/valsartan |
| Mean all-cause total cost of care of adult HFrEF patients treated with sacubitril/valsartan | All-cause total cost of care were defined as the sum of all-cause medical costs and all-cause pharmacy costs. | Baseline, 12 months post initiation of sacubitril/valsartan |